Each year, flu experts from around the world gather to map out recommendations for next winter's flu vaccine. This year, it's ...
Shares of Travere Therapeutics (NASDAQ:TVTX) surged 14% Tuesday following the company's announcement of a successful Type C ...
The Trump administration’s freeze on communications from U.S. health agencies is leading to another disruption: the abrupt ...
FDA’s Rare Disease Innovation Hub Releases Strategic Agenda: Implications for Stakeholders in 2025
In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...
U.S. District Judge John D. Bates granted a restraining order temporarily reversing the Trump administration’s moves to ...
The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or ...
Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...
The company is preparing for a pre-Investigational New Drug meeting with the U.S. FDA and plans to file an Investigational New Drug application for EL-22 in 2025, following successful preclinical ...
EL-22: Preparing for FDA Pre-IND Meeting Request: Northstrive is finalizing preparations for a pre-Investigational New Drug meeting request with the U.S. Food and Drug Administration. Northstrive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback